Preclinical evaluation of psoralen inactivation as a platform for developing a killed, whole cell vaccine for Enterotoxigenic E. coli (ETEC)

补骨脂素灭活作为开发产肠毒素大肠杆菌 (ETEC) 灭活全细胞疫苗的平台的临床前评估

基本信息

项目摘要

Westcott.Project Summary/Abstract Enterotoxigenic E. coli (ETEC), Shigella flexneri and Campylobacter jejuni are the predominant bacterial causes of morbidity and mortality from gastrointestinal (GI) disease in the developing world. Episodes of acute diarrhea caused by these agents have been linked to developmental defects and chronic GI syndromes. Vaccines that are safe for use in young children as well as adult travelers and deployed military are needed to prevent infection and post-infection sequellae caused by these organisms. Formalin inactivation is the current standard for generating killed, whole cell bacterial vaccines. This approach does not require genetic manipulations or extensive knowledge of antigens that induce protective immune responses. However, formalin crosslinks proteins, which has the potential to destroy antigenic epitopes that induce protective immune responses in the context of live bacterial infection. We propose to test the feasibility of an alternative inactivation method to generate safe, whole cell vaccines for enteric bacteria. Psoralen is a photoactivatable drug that reversibly intercalates into nucleic acids. Following irradiation with long wavelength UV light (P+UVA), covalent inter-strand crosslinks form at pyrimidine residues, preventing genome replication. Since P+UVA inactivates bacteria by crosslinking nucleic acids rather than proteins, we hypothesize that protein antigens will be preserved in a native form, generating vaccines with superior immunogenicity. We have successfully inactivated ETEC using P+UVA. With this proposal we will extend the ETEC work by comparing P+UVA to formalin-inactivated ETEC with respect to antigen preservation and immunogenicity using established in vitro assays and murine models. A direct comparative analysis of the 2 inactivation methods is needed to assess the value and feasibility of the P+UVA approach as an agile platform for enteric bacterial vaccines, and more generally for vaccines to prevent antibiotic-resistant bacterial infections that impact patient care in hospital settings. . 1
威斯克。项目总结/文摘

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The Immunogenicity and Properties of a Whole-Cell ETEC Vaccine Inactivated with Psoralen and UVA Light in Comparison to Formalin.
  • DOI:
    10.3390/microorganisms11082040
  • 发表时间:
    2023-08-09
  • 期刊:
  • 影响因子:
    4.5
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Marlena Moors Westcott其他文献

Marlena Moors Westcott的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 7.75万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.75万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 7.75万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.75万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 7.75万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.75万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 7.75万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 7.75万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 7.75万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.75万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了